Rogco LP Acquires 1,026 Shares of Johnson & Johnson $JNJ

Rogco LP raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,938 shares of the company’s stock after purchasing an additional 1,026 shares during the quarter. Johnson & Johnson accounts for 0.7% of Rogco LP’s portfolio, making the stock its 23rd largest holding. Rogco LP’s holdings in Johnson & Johnson were worth $1,824,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of JNJ. Highline Wealth Partners LLC boosted its position in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after buying an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson in the 1st quarter valued at $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on JNJ shares. Barclays upped their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Finally, UBS Group lifted their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $181.40.

Johnson & Johnson Price Performance

JNJ stock opened at $185.98 on Friday. The stock has a 50-day moving average price of $175.78 and a two-hundred day moving average price of $162.66. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $186.59. The stock has a market cap of $447.91 billion, a PE ratio of 19.89, a price-to-earnings-growth ratio of 2.37 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the company earned $2.82 earnings per share. The firm’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.